AlzeCure Pharma Resolves on a Directed Share Issue to QuantumCell
AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6) ("AlzeCure" or the "Company") announced in a press release on 1 July 2026 that the Company had entered into an out-licensing and collaboration agreement (the "Agreement") with the Danish company QuantumCell ApS regarding the NeuroRestore project ACD856. The press release disclosed, among other things, that part of the payment to AlzeCure would consist of a direct registration in the Company's...
Read more







